BioPortfolio Blog about Biotechnology, Pharmaceutical and Healthcare

16:17 EDT 23rd October 2016 | BioPortfolio

Updates and info from the contributors bringing you

Showing News Articles 1–5 of 2,400+

Saturday 22nd October 2016

Best Near-Term Price Gains Ahead For: Newer, Developing Biotechnology Stocks

Market-makers [MMs] hedge their clients' trades in these stocks every day, protecting their firm's capital temporarily put at risk filling large volume trade orders. That price-change insurance tells just how far the MMs expect those clients, who have the money muscle to make things happen, to push prices - both up and down.

Bernie Sanders: Stand up to Big Pharma greed. Vote yes on Proposition 61

Prescription drug prices in the United States are the highest in the world -- by far. Californians on Nov. 8 have a chance to stand up to the pharmaceutical industry's greed and spark a national movement to end this price-gouging.

Gilead Sciences Inc. (GILD) Rating Reiterated by Piper Jaffray Cos.

A number of other analysts have also issued reports on GILD. Zacks Investment Research raised shares of Gilead Sciences from a "sell" rating to a "hold" rating in a research note on Wednesday, June 29th.

PETA claims victory in stopping animal tests during sales talks

In its letter to the company, People for the Ethical Treatment of Animals said it had learned from a source that the practice from would continue at a sales meeting scheduled for later this month in Cincinnati. It urged its members to contact Johnson & Johnson to protest the teaching technique.

Cardinal Health, Inc. (NYSE: CAH) - Is this large market cap stock undervalued?

Cardinal Health, Inc. , is firmly in the large market cap category with market cap of 24204.5. To be considered a large market cap stock companies have to be valued at more than $10 billion. The current price for Cardinal Health, Inc. is 75.58 , this in conjunction with a target price of 89.87.

Quick Search